Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Janney Montgomery Scott Upgrades Agios Pharma (AGIO) to Buy
February 16, 2017 1:39 PM ESTJanney Montgomery Scott earlier upgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Buy with a price target of $57.00.
For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.
Shares of Agios Pharma closed at $46.12 yesterday.
... MoreAgios Pharma (AGIO) Tops Q4 EPS by 17c
February 16, 2017 7:04 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.34), $0.17 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $22.65 million versus the consensus estimate of $10.89 million.
"Our 2016 accomplishments, including the enasidenib NDA submission with our collaboration partner Celgene and clear proof-of-concept... More
